Summit Therapeutics Inc (SMMT) concluded trading on Wednesday at a closing price of $19.58, with 5.6 million shares of worth about $109.65 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.61% during that period and on June 11, 2025 the price saw a loss of about -11.32%. Currently the company’s common shares owned by public are about 741.61M shares, out of which, 110.30M shares are available for trading.
Stock saw a price change of 0.10% in past 5 days and over the past one month there was a price change of -22.49%. Year-to-date (YTD), SMMT shares are showing a performance of 9.72% which increased to 153.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.78 but also hit the highest price of $36.91 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 4.62 million. The stock is currently trading -13.49% below its 20-day simple moving average (SMA20), while that difference is down -16.15% for SMA50 and it goes to -5.09% lower than SMA200.
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 741.61M outstanding shares and institutions hold larger chunk of about 13.26% of that.
The stock has a current market capitalization of $14.44B and its 3Y-monthly beta is at -1.04. It has posted earnings per share of -$0.33 in the same period. It has Quick Ratio of 10.63 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 7.94% while standing at 9.87% over the month.
Stock’s fiscal year EPS is expected to drop by -30.60% while it is estimated to decrease by -33.86% in next year. EPS is likely to shrink at an annualized rate of -23.77% for next 5-years, compared to annual growth of -10.52% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on June 11, 2025 offering an Underperform rating for the stock and assigned a target price of $12 to it. Coverage by Citigroup stated Summit Therapeutics Inc (SMMT) stock as a Buy in their note to investors on March 26, 2025, suggesting a price target of $35 for the stock. On March 21, 2025, Cantor Fitzgerald Initiated their recommendations, while on March 12, 2025, Evercore ISI Initiated their ratings for the stock with a price target of $30. Stock get a Buy rating from Goldman on February 28, 2025.
